LME-54
Pharmaceutical compound
From Wikipedia, the free encyclopedia
LME-54, or simply LME, also known as lysergic acid methylethylamide or as N-methyl-N-ethyllysergamide, is a serotonergic psychedelic of the lysergamide family related to lysergic acid diethylamide (LSD; LSD-25).[2][3][4][5][1] It is the analogue of LSD in which one of the N-ethyl groups has been replaced with an N-methyl group.[2][3][4]
- None
| Clinical data | |
|---|---|
| Other names | LME54; LME; Lysergic acid methylethylamide; LA-methylethylamide; N-Ethyl-N-methyllysergamide; N-Ethyl-N,6-dimethyl-9,10-didehydroergoline-8β-carboxamide |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C19H23N3O |
| Molar mass | 309.413 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug was tested in humans at a dose of 25 μg and was found to produce no effects at this dose in several subjects and to produce weaker effects than a 25 μg dose of LSD in one subject.[1] Higher doses do not appear to have been assessed.[1] Based on these findings, LME-54 has been described as weakly active or active but less so than LSD with no specific numbers available.[2][3][4][5][6][7] Its antiserotonergic activity in vitro does not appear to have been reported.[6]
LME-54 was first described in the scientific literature by Harold Alexander Abramson and Andre Rolo by 1965.[1][8] It is not a controlled substance in Canada as of 2025.[9]
See also
- Substituted lysergamide
- Lysergic acid methylpropylamide (LMP-55)
- lysergic acid ethylpropylamide (LEP-57)
- Lysergic acid ethylamide (LAE-32)